FOLLOW US

  • facebook
  • twitter
Fri

March 20, 2026

AbbVie to Acquire Gilgamesh's Bretisilocin

America August 25, 2025

AbbVie to Acquire Gilgamesh’s Bretisilocin in $1.2B Psychedelic Bet

AbbVie Inc., advised by Covington & Burling LLP, has announced a blockbuster acquisition of Gilgamesh Pharmaceuticals’ lead psychedelic therapy candidate,…

By Rihem Akkouche

AbbVie $2B Licensing Agreement

America July 10, 2025

AbbVie Strikes $2B Licensing Deal with IGI Therapeutics

In a move that signals intensifying ambitions in the cancer therapeutics arena, pharmaceutical titan AbbVie Inc. unveiled Thursday a blockbuster…

By Rihem Akkouche

AbbVie Buys Celsius For $250M

America June 27, 2024

AbbVie Buys Celsius Therapeutics For $250M

Chicago-based pharmaceutical company AbbVie announced Thursday its acquisition of Celsius Therapeutics Inc., a privately held clinical-stage biotechnology firm focused on…

By Rihem Akkouche

AbbVie to buy Landos Biopharma for $212M

America March 25, 2024

AbbVie to buy Landos Biopharma for $212M

In a strategic move that sent shockwaves through the biopharmaceutical industry, AbbVie Inc. announced on Monday its intention to acquire…

By Rihem Akkouche

AbbieVie Buys ImmunoGen

America November 30, 2023

AbbieVie Buys ImmunoGen: A Groundbreaking $10.1 Billion Acquisition

In a stunning pre-market announcement, AbbVie Inc. has declared its intention to acquire ImmunoGen Inc., a prominent player in cancer…

By Rochdi Rais

AbbVie hQ

Brand Stories August 9, 2020

AbbVie to pay $24 million to settle lawsuit over Humira marketing practices

AbbVie (NYSE: ABBV) agreed to pay $24 million to settle a lawsuit alleging that the biopharmaceutical company committed wrongdoings in…

By Marivic Cabural Summers

FTC sues Beam Financial

Business May 6, 2020

FTC approves AbbVie’s proposed $63 billion deal to buy Allergan

The Federal Trade Commission (FTC) approved AbbVie’s (NYSE: ABBV) proposal to acquire Allergan (NYSE: AGN) for $63 billion after the…

By Marivic Cabural Summers

Signup for the USA Herald
exclusive Newsletter